Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 281.222.1782
To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >
Status: Open Not Enrolling
Investigator: Olga Waln
Study Coordinator: Yvonne Subhan
Phone: 346.238.9068
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with ... Read more >
Status: Open Not Enrolling
Investigator: Ivo Tremont-Lukats
Study Coordinator:
Phone:
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblatoma (GBM) or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 3 cohorts, Cohorts A, B, and ... Read more >
Status: Enrolling
Investigator: William Ondo
Study Coordinator: Chelsea Kinney
Phone: 346.238.9068
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. ... Read more >
Status: Enrolling
Investigator: William Ondo
Study Coordinator: Chelsea Kinney
Phone: 346.238.9068
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD. ... Read more >
Status: Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >
Status: Enrolling
Investigator: Gustavo Roman
Study Coordinator: Edwin Vega Vargas
Phone: 713.443.2044
This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive tes ... Read more >
Status: Open Not Enrolling
Investigator: Tetsuo Ashizawa
Study Coordinator:
Phone:
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >
Status: Enrolling
Investigator: Tetsuo Ashizawa
Study Coordinator: Valerie Flores
Phone: 713.363.9803
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >
Status: Open Not Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >
Status: Enrolling
Investigator: Olga Waln
Study Coordinator: Yvonne Subhan
Phone: 346.238.9068
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease. ... Read more >
Status: Enrolling
Investigator: Stanley Appel
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Maushami Gurung
Phone: 346.238.1565
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administere ... Read more >
Status: Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expand ... Read more >
Status: Open Not Enrolling
Investigator: Sherif Nagueh
Study Coordinator: Nirali Patel
Phone: 713.441.2116
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Benjamin Batista Ramos
Phone: 346.238.1259
The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging ... Read more >
Status: Open Not Enrolling
Investigator: Sheetal Shroff
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG). ... Read more >
Status: Open Not Enrolling
Investigator: Orlando Diaz
Study Coordinator:
Phone:
The primary objective of this study is to demonstrate effectiveness and safety of the NeuroForm Atlas stent system for use with bare metal embolic coils ... Read more >
Status: Enrolling
Investigator: Tetsuo Ashizawa
Study Coordinator: Valerie Flores
Phone: 713.363.9803
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known ... Read more >
Status: Open Not Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Manuel Navarro
Phone: 346.238.1564
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]). ... Read more >
Status: Open Not Enrolling
Investigator: Stanley Appel
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >
Status: Open Not Enrolling
Investigator: Stanley Appel
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Chimaoge Onyechi
Phone: 713.363.7729
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mech ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Andrea Franco Pando
Phone: 713.441.1150
The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abiliti ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Carlos Zarate
Phone: 713.441.1150
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator:
Phone:
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role ... Read more >
Status: Open Not Enrolling
Investigator: Vivek Misra
Study Coordinator:
Phone:
he primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-da ... Read more >
Status: Enrolling
Investigator: David Chiu
Study Coordinator:
Phone:
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours. ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >
Status: Open Not Enrolling
Investigator: David Baskin
Study Coordinator: Helga Jones
Phone: 713.363.9388
" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator:
Phone:
NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator: Melissa Cherry
Phone: 423.432.8699
NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >
Status: Enrolling
Investigator: Olga Waln
Study Coordinator: Shivani Desai
Phone: 713.363.8390
The purpose of this study is to determine whether a single treatment with administration of NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the arm (Unilateral Period). Participants wi ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 281.222.1782
The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >